ADC Manufacturing CDMOs

Shanghai Haoyuan Chemexpress Co., Ltd.

China

Shanghai Haoyuan ChemExpress Co., Ltd. (688131.SS) is a China-based integrated CRO/CDMO founded in 2006, specializing in small molecule and new modalities CDMO services for pharmaceutical and biotech companies. Listed on the Shanghai Stock Exchange, ChemExpress provides services spanning drug discovery CRO through commercial-scale CDMO, with recent expansion into ADC manufacturing via a new GMP production site.

STA Pharmaceutical Co., Ltd. (WuXi STA) is a subsidiary of WuXi AppTec and one of the world's leading CDMOs, specializing in integrated CMC services for small molecule APIs and drug products (oral and injectable/sterile) from preclinical to commercial scale. They also have capabilities in oligonucleotides, peptides, and bioconjugates. WuXi STA operates 9-14 global manufacturing sites across Asia, North America, and Europe with uniform quality/EHS standards approved by major regulators. They have supported 50+ first-time drug approvals since 2017 across 105 countries. The company has 5,100+ scientists, claims 100% PPQ success rate, and serves 1,200+ customers. Their Changzhou site has passed US FDA inspection and they have a continuous manufacturing line for oral solid dose.

TOT BIOPHARM is a China-based biopharmaceutical CDMO headquartered in Suzhou Industrial Park, providing end-to-end CDMO services with established technology platforms focused on biologics and ADC manufacturing. The company operates a large-scale GMP-compliant commercial production base with 20,000L monoclonal antibody drug substance capacity, and has achieved PMDA (Japan) accreditation. Listed on HKEX (1875.HK).

Galvita AG

Switzerland

Galvita AG is a Swiss excipient manufacturer based in Basel, specializing in the production and sale of pharmaceutical excipients. The company has a strategic partnership with Aenova Group and has been featured at CPHI and Swiss Biotech events. Galvita produces its own excipient products but does not offer contract drug manufacturing services.

Goodwin Biotechnology (GBI) is a full-service biopharmaceutical CDMO based in Florida, specializing in biologics development and manufacturing. Named Manufacturer of the Year by BioFlorida, GBI offers its Single-Source Solution for monoclonal antibodies, ADCs, recombinant proteins, and other complex biologics from cell line development through cGMP commercial manufacturing. The company provides mammalian cell culture manufacturing using CHO and other expression systems.

KriSan Biotech is a Taiwan-based CDMO founded in 2015, located in Tainan Science Park. They provide one-stop CDMO services for small molecule APIs, peptides, oligonucleotides, antibody-drug conjugates (ADC), and high-potency drugs from preclinical to commercialization. The company has a professional team averaging 10+ years of API experience. KriSan has partnered with CMIC BIO for ADC/XDC innovation, signed MoU with Mycenax for ADC capabilities, and has supplied kg-scale API to companies such as Atossa Genetics (NASDAQ: ATOS) and OncoArendi Therapeutics. They hold PIC/S GMP certification from TFDA.

LOTTE BIOLOGICS

South Korea

LOTTE BIOLOGICS is a global biologics CDMO headquartered in South Korea, offering end-to-end development and cGMP manufacturing services for biological Drug Substance. Operates the Syracuse Bio Campus (New York, USA) with 40,000L capacity and the Songdo Bio Campus (Incheon, South Korea) planned for 120,000L by 2027. Also operates a $100M ADC manufacturing facility.

MabPlex International

China

MabPlex International is a China-headquartered CDMO providing comprehensive biomanufacturing services for the global biopharmaceutical and biotechnology industry. They offer innovative CRO and CMO services for biologics, with facilities in China and the USA (MabPlex USA). They are expanding CDMO services and manufacturing capacity to meet global biologics demand, with multiple manufacturing sites.

SCI Pharmtech Inc. is a Taiwan-based API manufacturer originally founded by Switzerland-based Siegfried Ltd. in 1987, now publicly listed on the Taiwan Stock Exchange. The company specializes in APIs, advanced intermediates, and custom products with US FDA and EDQM inspected, ISO-certified facilities. SCI Pharmtech focuses on rapid development and cost-effective production.

Olon SpA is a global leader in the development and production of Active Pharmaceutical Ingredients (APIs) for CDMO and generic markets, integrating chemical synthesis and microbial biomanufacturing. The company operates 14 GMP facilities primarily in Italy, with additional sites in France (via GTP Bioways acquisition), the US, Germany, and China, with 450+ DMFs and 35+ years of regulatory experience.

CD BioGlyco is a supplier dedicated to advancing glycobiology research through high-quality products and services. The company provides various carbohydrates, glycoconjugates, enzymes, and related products, as well as glycobiology-related research services. It is primarily a research reagent and specialty biochemical supplier, not a pharmaceutical contract manufacturer.

Gellycle Co., Ltd. is a Japanese company developing innovative technologies for controlling the physical properties of hydrogels, operating a platform-type business providing hydrogel solutions. The company participates in pharma industry events (INTERPHEX Tokyo) and Swiss Biotech Days, but appears to be a technology/materials company rather than a contract drug manufacturer.

Mycenax Biotech is a Taiwan-based biologics CDMO specializing in the development and manufacturing of biosimilars, monoclonal antibodies, bispecific antibodies, ADCs, and cell & gene therapy-related products. The company provides integrated services spanning cell line development, process development, analytical services, GMP manufacturing, and regulatory support for global biotech and pharmaceutical partners. With expertise in mammalian cell culture and biologics manufacturing, Mycenax supports clients from early-stage development through commercial-scale production. The company has established GMP facilities in Taiwan and focuses on delivering flexible, high-quality manufacturing solutions for complex biologics and next-generation therapeutics.